BR0014583A - Receptor april (bcma) e seus usos - Google Patents

Receptor april (bcma) e seus usos

Info

Publication number
BR0014583A
BR0014583A BR0014583-1A BR0014583A BR0014583A BR 0014583 A BR0014583 A BR 0014583A BR 0014583 A BR0014583 A BR 0014583A BR 0014583 A BR0014583 A BR 0014583A
Authority
BR
Brazil
Prior art keywords
bcma
april
receptor
april receptor
antibodies
Prior art date
Application number
BR0014583-1A
Other languages
English (en)
Inventor
Pascal Schneider
Jeffrey Thompson
Teresa Cachero
Christiane Ambrose
Paul Rennert
Original Assignee
Biogen Inc
Apotech R & D Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27388102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0014583(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc, Apotech R & D Sa filed Critical Biogen Inc
Publication of BR0014583A publication Critical patent/BR0014583A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: "RECEPTOR APRIL (BCMA) E SEUS USOS". Um receptor na família de TNF é fornecido: APRIL-R. Moléculas quiméricas e anticorpos para APRIL-R e métodos de seu uso são também fornecidos.
BR0014583-1A 1999-10-06 2000-10-05 Receptor april (bcma) e seus usos BR0014583A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15793399P 1999-10-06 1999-10-06
US18180700P 2000-02-11 2000-02-11
US21568800P 2000-06-30 2000-06-30
PCT/US2000/027579 WO2001024811A1 (en) 1999-10-06 2000-10-05 April receptor (bcma) and uses thereof

Publications (1)

Publication Number Publication Date
BR0014583A true BR0014583A (pt) 2002-06-11

Family

ID=27388102

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014583-1A BR0014583A (pt) 1999-10-06 2000-10-05 Receptor april (bcma) e seus usos

Country Status (30)

Country Link
US (1) US7276241B2 (pt)
EP (3) EP2324844A3 (pt)
JP (2) JP4880155B2 (pt)
KR (1) KR100759295B1 (pt)
CN (1) CN1263507C (pt)
AT (1) ATE360434T1 (pt)
AU (1) AU776852B2 (pt)
BG (1) BG65473B1 (pt)
BR (1) BR0014583A (pt)
CA (1) CA2386463C (pt)
CZ (1) CZ297633B6 (pt)
DE (1) DE60034586T2 (pt)
DK (1) DK1223964T3 (pt)
EA (1) EA005601B1 (pt)
EE (1) EE05212B1 (pt)
GE (1) GEP20043375B (pt)
HK (1) HK1044710B (pt)
HU (1) HUP0203567A2 (pt)
IL (3) IL148839A0 (pt)
IS (1) IS6322A (pt)
MX (1) MXPA02003393A (pt)
NO (1) NO331683B1 (pt)
NZ (1) NZ517907A (pt)
PL (1) PL204010B1 (pt)
RS (1) RS51602B (pt)
SK (1) SK286331B6 (pt)
TR (1) TR200200912T2 (pt)
UA (1) UA74798C2 (pt)
WO (1) WO2001024811A1 (pt)
ZA (1) ZA200202578B (pt)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
PL211786B1 (pl) 1999-08-17 2012-06-29 Apoxis Sa Zastosowanie przeciwciała oraz polipeptydu
AU2048501A (en) * 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7371388B1 (en) 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
DE60128216T2 (de) * 2000-05-12 2008-01-10 Amgen Inc., Thousand Oaks Polypeptide zum Hemmen der April-vermittelten Proliferation von B- und T- Zellen
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CA2446734A1 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
EA010594B1 (ru) 2001-05-24 2008-10-30 Займодженетикс, Инк. Слитые белки taci-иммуноглобулина
CA2453995A1 (en) * 2001-08-03 2003-02-20 Genentech, Inc. Tacis and br3 polypeptides and uses thereof
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP1516054B1 (de) 2002-02-10 2009-12-02 Topotarget Switzerland SA Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
US20080267965A1 (en) * 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
US20050043516A1 (en) * 2002-07-25 2005-02-24 Genentech, Inc. TACI antibodies and uses thereof
AU2004233164B2 (en) 2003-03-28 2009-10-08 Biogen Ma Inc. Truncated BAFF receptors
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
PT2272868E (pt) * 2003-06-05 2015-07-07 Genentech Inc Terapêutica de combinação para distúrbios de células b
RU2006117324A (ru) 2003-10-20 2007-12-10 Байоджен Айдек Ма Инк. (Us) Терапевтические режимы для антагонистов baff
NZ550816A (en) 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CN1786016B (zh) * 2004-12-09 2010-12-29 中国人民解放军军事医学科学院基础医学研究所 一种人工构建的生物活性分子及其制备方法
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
CA2596276A1 (en) * 2005-01-28 2006-08-03 Biogen Idec Ma Inc. Use of baff to treat th2-mediated conditions
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
CN101262876A (zh) 2005-08-09 2008-09-10 酶遗传学股份有限公司 用taci-ig融合分子治疗b细胞恶性肿瘤的方法
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
AU2007308792B2 (en) * 2006-10-27 2013-01-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
US20120201823A1 (en) * 2009-10-14 2012-08-09 Schering Corporation April antagonists and methods of use
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013171296A1 (en) 2012-05-16 2013-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic and treatment of sarcoidosis
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
ES2731232T3 (es) 2013-03-15 2019-11-14 Inst Nat Sante Rech Med Método y composición farmacéutica para su uso en el tratamiento y la predicción del infarto de miocardio
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
BR112016011004A2 (pt) * 2013-11-19 2017-12-05 Regeneron Pharma animal roedor geneticamente modificado, célula tronco embrionária de roedor, embrião de roedor, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
US20170247462A1 (en) 2014-07-03 2017-08-31 Oklahoma Medical Research Foundation Treatment of multiple sclerosis and neuromyelitis optica
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
AU2016302881B2 (en) 2015-08-03 2022-09-15 Bristol-Myers Squibb Company Monoclonal antibodies against BCMA
WO2017031104A1 (en) 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
AU2016353067B2 (en) * 2015-11-13 2023-10-05 Sanford Research Anti-BCMA polypeptides and proteins
DK3380522T5 (da) 2015-11-25 2024-09-30 Visterra Inc Antistofmolekyler til april og anvendelser deraf
IL311107A (en) 2016-02-17 2024-04-01 Seagen Inc BCMA antibodies and their use for the treatment of cancer and immune disorders
CN109641049B (zh) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 Cd3结合抗体
MY200988A (en) 2016-09-14 2024-01-27 Teneobio Inc CD3 Binding Antibodies
EP3535295A1 (en) 2016-11-02 2019-09-11 EngMab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
IL312322B2 (en) 2017-06-20 2026-05-01 Teneobio Inc Antibodies against BCMA containing only heavy chains
WO2018237006A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
SG11202011306TA (en) 2018-05-16 2020-12-30 Janssen Biotech Inc Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
BR112020024074A2 (pt) 2018-07-20 2021-02-17 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd19
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
JP7665538B2 (ja) 2019-06-14 2025-04-21 テネオバイオ， インコーポレイテッド Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
BR112022001546A2 (pt) 2019-07-30 2022-03-22 Jiangsu Hansoh Pharmaceutical Group Co Ltd Anticorpo anti-bcma, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2021222578A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
IL297601A (en) 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
PH12022553023A1 (en) 2020-05-11 2024-03-04 Janssen Biotech Inc Methods for treating multiple myeloma
CN115996748A (zh) * 2020-05-29 2023-04-21 奇努克医疗公司 用APRIL结合抗体治疗IgA肾病的方法
PE20230464A1 (es) 2020-06-30 2023-03-14 Teneobio Inc Union de anticuerpos multiespecificos a bcma
IL305144A (en) 2021-02-16 2023-10-01 Janssen Pharmaceutica Nv Trispecific antibodies targeting BCMA, GPRC5D and CD3
JP2024515591A (ja) 2021-04-08 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｔｃｒに結合する多機能性分子およびその使用
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
EP4384201A4 (en) 2021-08-11 2025-07-30 Akso Biopharmaceutical Inc METHODS FOR REDUCING THE PRODUCTION OF IGA, IGM AND/OR IGG IMMUNOGLOBULINS USING SBCMA VARIANTS AND THEIR FC FUSION PROTEINS
WO2023081705A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
CN121263449A (zh) 2023-03-21 2026-01-02 拜格拉夫55公司 Cd19/cd38多特异性抗体
WO2025134050A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
WO2025134049A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
WO2025174963A1 (en) 2024-02-16 2025-08-21 Kite Pharma, Inc. Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2026061495A1 (zh) * 2024-09-20 2026-03-26 长春金赛药业有限责任公司 一种阻断BAFF、APRIL作用其受体的Fc融合蛋白

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US6218510B1 (en) * 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
EP1362916A3 (en) 1996-03-14 2004-02-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
DK0939804T4 (da) 1996-10-25 2011-07-18 Human Genome Sciences Inc Neutrokin-alpha
WO1998027114A2 (en) 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
CA2292899A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
IL133315A0 (en) 1997-06-06 2001-04-30 Regeneron Pharma Ntn-2 member of tnf ligand family
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
BR9812634A (pt) * 1997-09-12 2000-08-22 Biogen Inc April - uma proteìna com efeitos de crescimento
IL134480A0 (en) * 1997-09-12 2001-04-30 Apotech Sa Kay - an immune system protein and dna sequences encoding the same
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
AU1467000A (en) 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
TR200101998T2 (tr) * 1999-01-07 2002-06-21 Zymogenetics, Inc. Çözünür reseptör BR 43x2 ve kullanım metodları
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
ATE515267T1 (de) 1999-01-25 2011-07-15 Biogen Idec Inc Verwendung eines antikörpers gegen wasserlöslich baff zur krebsbehandlung
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
EP1860190A3 (en) 1999-02-23 2008-03-12 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variants
WO2000050633A1 (en) * 1999-02-24 2000-08-31 The General Hospital Corporation Method for cloning signal transduction intermediates
AU3633000A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
AU4986700A (en) 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
PL211786B1 (pl) * 1999-08-17 2012-06-29 Apoxis Sa Zastosowanie przeciwciała oraz polipeptydu
JP2003521931A (ja) 2000-02-11 2003-07-22 バイオジェン インコーポレイテッド Ｔｎｆファミリーの異種ポリペプチド
AU2048501A (en) * 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
DE60128216T2 (de) 2000-05-12 2008-01-10 Amgen Inc., Thousand Oaks Polypeptide zum Hemmen der April-vermittelten Proliferation von B- und T- Zellen
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
AU2001288260A1 (en) 2000-08-15 2002-03-13 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys

Also Published As

Publication number Publication date
JP4880155B2 (ja) 2012-02-22
PL204010B1 (pl) 2009-12-31
SK4512002A3 (en) 2002-12-03
SK286331B6 (en) 2008-07-07
EA005601B1 (ru) 2005-04-28
IL148839A0 (en) 2002-09-12
KR100759295B1 (ko) 2007-09-18
EP2324844A2 (en) 2011-05-25
ATE360434T1 (de) 2007-05-15
CA2386463C (en) 2012-02-07
CZ297633B6 (cs) 2007-02-14
DE60034586T2 (de) 2008-02-28
IL204401A (en) 2014-12-31
AU7864500A (en) 2001-05-10
EE05212B1 (et) 2009-10-15
YU25302A (sh) 2005-06-10
EE200200181A (et) 2003-06-16
HK1044710B (en) 2007-12-07
BG106670A (en) 2002-12-29
CN1263507C (zh) 2006-07-12
MXPA02003393A (es) 2004-08-19
EP1847273A1 (en) 2007-10-24
WO2001024811A1 (en) 2001-04-12
DK1223964T3 (da) 2007-08-27
HUP0203567A2 (hu) 2003-02-28
US7276241B2 (en) 2007-10-02
US20030082175A1 (en) 2003-05-01
EP1223964A1 (en) 2002-07-24
CZ20021169A3 (cs) 2002-09-11
KR20020053066A (ko) 2002-07-04
RS51602B (sr) 2011-08-31
NZ517907A (en) 2004-01-30
EP2324844A3 (en) 2013-12-11
ZA200202578B (en) 2003-07-02
JP2003510366A (ja) 2003-03-18
EP1223964B1 (en) 2007-04-25
BG65473B1 (bg) 2008-09-30
AU776852B2 (en) 2004-09-23
IL148839A (en) 2015-01-29
JP2011079863A (ja) 2011-04-21
UA74798C2 (uk) 2006-02-15
TR200200912T2 (tr) 2002-07-22
GEP20043375B (en) 2004-11-25
IS6322A (is) 2002-03-22
NO331683B1 (no) 2012-02-20
DE60034586D1 (de) 2007-06-06
NO20021594D0 (no) 2002-04-04
CA2386463A1 (en) 2001-04-12
CN1399556A (zh) 2003-02-26
HK1044710A1 (en) 2002-11-01
NO20021594L (no) 2002-06-05
PL355102A1 (en) 2004-04-05
EA200200427A1 (ru) 2002-12-26

Similar Documents

Publication Publication Date Title
ATE360434T1 (de) April rezeptor (bcma) und verwendungen davon
YU10602A (sh) Upotreba baff receptora imunoregulatornog agensa
BR9909860A (pt) Polipeptìdeos cd19xcd3 especìficos e usos dos mesmos
MA25872A1 (fr) Materiaux multi-usage sous forme de feuilles absorbant et resistant au dechirement
ATE473243T1 (de) Humane monoklonale antikörper gegen das kostimulatorische signaltransduktionsmolekül ailim und pharmazeutische verwendungen davon
PT1270565E (pt) Furano-2-sulfonamida 4-substituida e sua utilizacao na preparacao de derivados de sulfonilureia
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
BR0110968A (pt) Antagonistas dos receptores de il-8
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
CO4290432A1 (es) Nuevos derivados de pirazinacarboxamida, su preparacion y su utilizacion en medicamentos.
BR9707339A (pt) Composição de cuidado pessoal na forma de um líquido aquoso e uso da mesma
IT8848231A0 (it) Sintesi di derivati di glicosfingolipidi ed in particolare di gangliosidi utilizzabili per la preparazione di immunoadsorbenti ed adsorbenti per affinita' impiegabili per la purificazione di anticorpi e di tossine specifiche, e per uso diagnostico
BR9912153A (pt) Piperazinonas substituìdas e uso terapêuticos das mesmas
IT1302368B1 (it) Dispositivo per ridurre il volume di bottiglie termoplastiche vuotemediante l'uso di vapore
BR0010985A (pt) Antagonistas de receptor de il-8
ITFI990040A0 (it) Uso della metformina per la preparazione di composizioni farmaceutiche per determinare l'aumento della concentrazione plasmatica di glucagon
DK0438358T3 (da) Fast og porøs enhedsform indeholdende partikler i form af perler samt dens fremstilling
EE200900055A (et) TNF/NFG retseptoriperekonna retseptorite ja muude valkude talitluse modulaatorid, nende valmistamine ja kasutamine ning farmatseutiline kompositsioon
ITTO910067V0 (it) Dispositivo per facilitare l'uso di strumenti per la scrittura
FR2604626B1 (fr) Composition liquide ayant des vertus d'empecher le ronflement
ITBO940298A0 (it) Sistema per evitare il reimpiego delle posate monouso nei pubblici.
ITPD920214A1 (it) Formulazioni per promuovere l'assorbimento vaginale di polipeptidi

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: APOTECH RANDD S.A. (CH) , BIOGEN IDEC MA, INC. (US

Free format text: ALTERADO DE: BIOGEN, INC.

B25D Requested change of name of applicant approved

Owner name: APOTECH RANDD S.A. (CH) , BIOGEN IDEC MA INC. (US)

Free format text: ALTERADO DE: BIOGEN IDEC MA, INC.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 37, 10 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.